NASDAQ:AMGN - Amgen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$178.36 +1.89 (+1.07 %)
(As of 05/23/2018 05:11 AM ET)
Previous Close$176.47
Today's Range$176.51 - $179.57
52-Week Range$152.16 - $201.23
Volume2.74 million shs
Average Volume3.52 million shs
Market Capitalization$116.77 billion
P/E Ratio14.18
Dividend Yield2.99%
Beta1.36

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000

Debt

Debt-to-Equity Ratio2.14
Current Ratio3.88
Quick Ratio3.60

Price-To-Earnings

Trailing P/E Ratio14.18
Forward P/E Ratio13.00
P/E Growth2.18

Sales & Book Value

Annual Sales$22.85 billion
Price / Sales5.17
Cash Flow$15.5909 per share
Price / Cash11.44
Book Value$23.61 per share
Price / Book7.55

Profitability

EPS (Most Recent Fiscal Year)$12.58
Net Income$1.98 billion
Net Margins9.67%
Return on Equity35.80%
Return on Assets12.06%

Miscellaneous

Employees20,800
Outstanding Shares661,710,000

Amgen (NASDAQ:AMGN) Frequently Asked Questions

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Wednesday, March 7th. Stockholders of record on Thursday, May 17th will be given a dividend of $1.32 per share on Friday, June 8th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date of this dividend is Wednesday, May 16th. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen announced that its Board of Directors has initiated a stock repurchase program on Friday, February 2nd 2018, which permits the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board believes its stock is undervalued.

How were Amgen's earnings last quarter?

Amgen (NASDAQ:AMGN) posted its quarterly earnings data on Tuesday, April, 24th. The medical research company reported $3.47 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $3.24 by $0.23. The medical research company earned $5.55 billion during the quarter, compared to analyst estimates of $5.44 billion. Amgen had a net margin of 9.67% and a return on equity of 35.80%. The business's revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the business earned $3.15 earnings per share. View Amgen's Earnings History.

When is Amgen's next earnings date?

Amgen is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $12.80-13.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $13.47. The company issued revenue guidance of $21.9-22.8 billion, compared to the consensus revenue estimate of $22.71 billion.

What price target have analysts set for AMGN?

22 brokerages have issued twelve-month price targets for Amgen's shares. Their predictions range from $161.00 to $220.00. On average, they expect Amgen's share price to reach $192.1058 in the next twelve months. View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:
  • 1. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Kyprolis – are performing well.  Amgen is also progressing with its pipeline and expects approval and launch of migraine candidate, Aimovig this year. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support in 2018. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions. However, estimates have gone up ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/17/2018)
  • 2. JPMorgan Chase analysts commented, "AMGN’s top-line continues to be uninspiring, but the bottom line will meaningfully benefit from a lower than expected tax rate (surprise, surprise) and a large, accelerated $10B share buyback. There are several moving pieces to consider heading into 2018 (which are apparent in management’s uncharacteristically wide guidance range), including timing/magnitude of legacy franchise erosion (e.g., Neulasta & Sensipar), trajectory of recent/upcoming launches (e.g., Kyprolis, Repatha, Aimovig), and the extent to which AMGN chooses to exercise its upsized share repurchase authorization (now ~$14B in total). While we continue to be keenly interested in potential for M&A (which AMGN continues to be constructive on) and the earlier stage pipeline, we maintain our Neutral rating pending evidence of sustainable near-/mid-term growth." (2/4/2018)
  • 3. Mizuho analysts commented, "We expect Q4 ’17 trends for both unit demand and net selling price to continue into 2018 – Expect Q1 ’18 sales to be ~ 20% of full year 2018 sales Neulasta US = 969 / 950 / 949 Neulasta Ex-US = 145 / 151 / 152 Neulasta WW = 1114/ 1103 / 1100 Neupogen US = 82 / 87 / 87 PLEASE REFER TO PAGE 5 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (2/1/2018)
  • 4. Cann analysts commented, "Amgen yesterday announced that the New England Journal of Medicine (NEJM) published positive results from the six-month phase III STRIVE study evaluating Aimovig (erenumab) versus placebo for the prevention of episodic migraine (between four and 14 migraine days per month). The NEJM article reported that Aimovig delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study." (11/30/2017)
  • 5. Argus analysts commented, "We would consider a more constructive stance on AMGN on signs of stronger contributions from the company's new drug pipeline or from its biosimilars portfolio," the firm said."We note, however, that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal hurdles." (11/1/2017)

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 55)
  • Mr. David W. Meline, Exec. VP, CFO and Principal Financial & Accounting Officer (Age 61)
  • Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 57)
  • Dr. Sean E. Harper, Exec. VP of R&D (Age 55)
  • Mr. Anthony C. Hooper, Exec. VP of Global Commercial Operations (Age 63)

Has Amgen been receiving favorable news coverage?

Headlines about AMGN stock have been trending somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Amgen earned a media sentiment score of 0.15 on Accern's scale. They also assigned news articles about the medical research company an impact score of 46.02 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Amgen's major shareholders?

Amgen's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.08%), Northern Trust Corp (1.40%), Wells Fargo & Company MN (0.97%), Franklin Resources Inc. (0.61%), LSV Asset Management (0.61%) and Legal & General Group Plc (0.52%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Institutional Ownership Trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., BlackRock Inc., Wells Fargo & Company MN, Northern Trust Corp, Swiss National Bank, The Manufacturers Life Insurance Company , State of Tennessee Treasury Department and Great Lakes Advisors LLC. Company insiders that have sold Amgen company stock in the last year include Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Insider Buying and Selling for Amgen.

Which institutional investors are buying Amgen stock?

AMGN stock was bought by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, Old Mutual Global Investors UK Ltd., Summit Trail Advisors LLC, SG Americas Securities LLC, Mackay Shields LLC, LSV Asset Management, Element Capital Management LLC and Coho Partners Ltd.. View Insider Buying and Selling for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $178.36.

How big of a company is Amgen?

Amgen has a market capitalization of $116.77 billion and generates $22.85 billion in revenue each year. The medical research company earns $1.98 billion in net income (profit) each year or $12.58 on an earnings per share basis. Amgen employs 20,800 workers across the globe.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]


MarketBeat Community Rating for Amgen (AMGN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,051 (Vote Outperform)
Underperform Votes:  676 (Vote Underperform)
Total Votes:  1,727
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amgen (NASDAQ:AMGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
22 Wall Street analysts have issued ratings and price targets for Amgen in the last 12 months. Their average twelve-month price target is $192.1058, suggesting that the stock has a possible upside of 7.71%. The high price target for AMGN is $220.00 and the low price target for AMGN is $161.00. There are currently 12 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.452.432.432.48
Ratings Breakdown: 0 Sell Rating(s)
12 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
13 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
13 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $192.1058$190.8505$191.8576$190.1053
Price Target Upside: 7.71% upside11.47% upside10.61% upside8.50% upside

Amgen (NASDAQ:AMGN) Consensus Price Target History

Price Target History for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018MizuhoSet Price TargetBuy$200.00HighView Rating Details
4/25/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$205.00 ➝ $200.00MediumView Rating Details
4/25/2018Royal Bank of CanadaLower Price TargetSector Perform$183.00HighView Rating Details
4/24/2018CowenReiterated RatingBuy$204.00MediumView Rating Details
4/5/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$190.00 ➝ $180.00LowView Rating Details
2/5/2018Atlantic SecuritiesDowngradeOverweight ➝ Neutral$187.01HighView Rating Details
2/4/2018JPMorgan ChaseReiterated RatingHold$191.00HighView Rating Details
2/2/2018Leerink SwannReiterated RatingMarket PerformHighView Rating Details
2/2/2018Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$191.00 ➝ $194.00LowView Rating Details
2/2/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$192.00 ➝ $202.00MediumView Rating Details
2/2/2018Piper Jaffray CompaniesLower Price TargetOverweight ➝ Overweight$194.00 ➝ $190.00MediumView Rating Details
1/30/2018OppenheimerReiterated RatingBuy$205.00 ➝ $205.00LowView Rating Details
1/23/2018ArgusUpgradeHold ➝ Buy$192.33 ➝ $220.00LowView Rating Details
12/18/2017CitigroupDowngradeNeutralLowView Rating Details
12/15/2017Goldman SachsDowngradeConviction-Buy ➝ BuyHighView Rating Details
11/30/2017CannReiterated RatingBuy$205.00HighView Rating Details
10/5/2017Bank of AmericaBoost Price TargetBuy$210.00N/AView Rating Details
9/25/2017Jefferies GroupReiterated RatingBuy$200.00LowView Rating Details
7/26/2017UBSSet Price TargetHold$175.00 ➝ $180.00HighView Rating Details
7/26/2017Deutsche BankReiterated RatingHold$172.00 ➝ $174.00LowView Rating Details
6/26/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/8/2017Sanford C. BernsteinSet Price TargetHold$164.00MediumView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
12/13/2016Chardan CapitalUpgradeSell ➝ NeutralN/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Amgen (NASDAQ:AMGN) Earnings History and Estimates Chart

Earnings by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Earnings Estimates

2018 EPS Consensus Estimate: $13.69
2019 EPS Consensus Estimate: $14.08
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$3.16$3.50$3.31
Q2 20184$3.54$3.66$3.61
Q3 20184$3.30$3.72$3.51
Q4 20184$3.11$3.45$3.26
Q1 20192$3.53$3.54$3.54
Q2 20192$3.49$3.62$3.56
Q3 20192$3.51$3.65$3.58
Q4 20192$3.28$3.54$3.41

Amgen (NASDAQ AMGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/23/2018$3.54N/AView Earnings Details
4/24/2018Q1 2018$3.24$3.47$5.4417 billion$5.5540 billionViewN/AView Earnings Details
2/1/2018Q4 2017$3.03$2.89$5.8428 billion$5.8020 billionViewListenView Earnings Details
10/25/2017Q3 2017$3.11$3.27$5.7510 billion$5.7730 billionViewN/AView Earnings Details
7/25/2017Q2 2017$3.11$3.27$5.6656 billion$5.81 billionViewN/AView Earnings Details
4/26/2017Q1 2017$3.00$3.15$5.6047 billion$5.4640 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.9650 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.8110 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.6880 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.7230 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.0330 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.7569 billion$4.5210 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.4909 billion$4.6790 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.2380 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.4210 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
4/24/2012Q1 2012$1.43$1.59ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
10/25/2010Q3 2010$1.26$1.36ViewN/AView Earnings Details
7/29/2010Q2 2010$1.28$1.34ViewN/AView Earnings Details
4/21/2010Q1 2010$1.23$1.28ViewN/AView Earnings Details
1/25/2010Q4 2009$1.11$1.05ViewN/AView Earnings Details
10/21/2009Q3 2009$1.25$1.49ViewN/AView Earnings Details
7/27/2009Q2 2009$1.15$1.27ViewN/AView Earnings Details
4/23/2009Q1 2009$1.13$1.08ViewN/AView Earnings Details
1/26/2009Q4 2008$1.04$1.04ViewN/AView Earnings Details
10/22/2008Q3 2008$1.06$1.21ViewN/AView Earnings Details
7/28/2008Q2 2008$0.98$1.13ViewN/AView Earnings Details
4/24/2008Q1 2008$1.02$1.10ViewN/AView Earnings Details
1/24/2008Q4 2007$0.92$0.97ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Amgen (NASDAQ:AMGN) Dividend Information

Amgen pays an annual dividend of $5.28 per share, with a dividend yield of 2.96%. AMGN's next quarterly dividend payment will be made on Friday, June 8. The company has grown its dividend for the last 7 consecutive years and is increasing its dividend by an average of 23.50% each year. Amgen pays out 41.97% of its earnings out as a dividend.
Next Dividend:6/8/2018
Annual Dividend:$5.28
Dividend Yield:2.96%
Dividend Growth:23.50% (3 Year Average)
Payout Ratio(s):41.97% (Trailing 12 Months of Earnings)
38.48% (Based on This Year's Estimates)
37.42% (Based on Next Year's Estimates)
33.87% (Based on Cash Flow)
Track Record:7 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/7/2018quarterly$1.322.81554951207807%5/16/20185/17/20186/8/2018
12/12/2017quarterly$1.322.98%2/14/20182/15/20183/8/2018
10/24/2017quarterly$1.152.59%11/16/201711/17/201712/8/2017
7/28/2017quarterly$1.152.64%8/15/20178/17/20179/8/2017
3/7/2017quarterly$1.152.59%5/15/20175/17/20176/8/2017
12/20/2016quarterly$1.153.15%2/13/20172/15/20173/8/2017
10/14/2016quarterly$1.002.46%11/14/201611/16/201612/8/2016
7/22/2016quarterly$1.002.4%8/15/20168/17/20169/8/2016
3/2/2016quarterly$1.002.74%5/13/20165/17/20166/8/2016
12/15/2015quarterly$1.002.43%2/11/20162/16/20163/8/2016
10/14/2015quarterly$0.792.07%11/12/201511/16/201512/7/2015
7/28/2015quarterly$0.791.84%8/13/20158/17/20159/8/2015
3/4/2015quarterly$0.791.98%5/12/20155/14/20156/5/2015
12/17/2014quarterly$0.791.88%2/10/20152/12/20153/6/2015
10/17/2014quarterly$0.611.77%11/10/201411/13/201412/5/2014
7/25/2014quarterly$0.611.99%8/12/20148/14/20149/5/2014
3/5/2014quarterly$0.611.96%5/13/20145/15/20146/6/2014
12/13/2013quarterly$0.612.18%2/11/20142/13/20143/7/2014
10/16/2013quarterly$0.471.62%11/12/201311/14/201312/6/2013
7/26/2013quarterly$0.471.72%8/14/20138/16/20139/6/2013
3/6/2013quarterly$0.472.02%5/14/20135/16/20136/7/2013
12/13/2012quarterly$0.472.11%2/11/20132/13/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Amgen (NASDAQ AMGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.27%
Institutional Ownership Percentage: 78.43%
Insider Trading History for Amgen (NASDAQ:AMGN)
Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ AMGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2018Sean E. HarperEVPSell1,525$174.10$265,502.50View SEC Filing  
4/12/2018Sean E. HarperEVPSell1,525$172.68$263,337.00View SEC Filing  
3/16/2018Sean E. HarperEVPSell1,525$189.75$289,368.75View SEC Filing  
2/14/2018Sean E. HarperEVPSell1,525$174.18$265,624.50View SEC Filing  
1/16/2018Sean E. HarperEVPSell1,525$185.62$283,070.50View SEC Filing  
12/12/2017Sean E HarperEVPSell1,525$176.83$269,665.7556,106View SEC Filing  
11/13/2017Sean E HarperEVPSell1,525$171.58$261,659.5057,631View SEC Filing  
11/8/2017Carbonnel Francois DeDirectorSell4,000$173.61$694,440.00View SEC Filing  
10/9/2017Sean E HarperEVPSell1,525$185.95$283,573.75View SEC Filing  
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.8024,214View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.0023,097View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.5232,350View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.2542,248View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.0015,150View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.303,582View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.9018,589View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.2541,041View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.0018,343View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.1226,879View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amgen (NASDAQ AMGN) News Headlines

Source:
DateHeadline
BRIEF-Amgen Inc Says All Director Nominees Re-Elected To BoardBRIEF-Amgen Inc Says All Director Nominees Re-Elected To Board
www.reuters.com - May 22 at 5:22 PM
Amgens Label Expansion Application for Prolia Gets FDA NodAmgen's Label Expansion Application for Prolia Gets FDA Nod
www.nasdaq.com - May 22 at 5:22 PM
Amgen Announces Voting Results Of Annual Meeting Of StockholdersAmgen Announces Voting Results Of Annual Meeting Of Stockholders
finance.yahoo.com - May 22 at 5:22 PM
Regional cycling fans show up in numbers for Amgen Tour (PHOTOS)Regional cycling fans show up in numbers for Amgen Tour (PHOTOS)
finance.yahoo.com - May 22 at 8:01 AM
New Migraine Drugs Offer Hope to SufferersNew Migraine Drugs Offer Hope to Sufferers
finance.yahoo.com - May 22 at 8:01 AM
Amgen (AMGN) Reports FDA Approval of Prolia (Denosumab) For Glucocorticoid-Induced OsteoporosisAmgen (AMGN) Reports FDA Approval of Prolia (Denosumab) For Glucocorticoid-Induced Osteoporosis
www.streetinsider.com - May 21 at 5:27 PM
FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced OsteoporosisFDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
finance.yahoo.com - May 21 at 5:27 PM
FY2020 Earnings Estimate for Amgen Issued By Leerink Swann (AMGN)FY2020 Earnings Estimate for Amgen Issued By Leerink Swann (AMGN)
www.americanbankingnews.com - May 21 at 2:00 AM
Amgen Says Just-Approved Migraine Drug Will Cost $6900 a YearAmgen Says Just-Approved Migraine Drug Will Cost $6900 a Year
www.bloomberg.com - May 18 at 9:17 AM
Todays Research Reports on Trending Tickers: Amgen and AllerganToday's Research Reports on Trending Tickers: Amgen and Allergan
finance.yahoo.com - May 18 at 9:17 AM
Amgens first mover advantage with Aimovig bodes well - analystsAmgen's first mover advantage with Aimovig bodes well - analysts
seekingalpha.com - May 18 at 8:49 AM
Amgen (AMGN) Given Average Rating of "Hold" by AnalystsAmgen (AMGN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 18 at 1:10 AM
FDA approves new Amgen drug for prevention of migrainesFDA approves new Amgen drug for prevention of migraines
www.cnbc.com - May 17 at 9:48 PM
Expanded label for Amgens Repatha approved in EuropeExpanded label for Amgen's Repatha approved in Europe
seekingalpha.com - May 17 at 8:18 AM
BRIEF-Amgen Receives European Commission Approval For Repatha (Evolocumab)BRIEF-Amgen Receives European Commission Approval For Repatha (Evolocumab)
www.reuters.com - May 16 at 5:49 PM
Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In ...Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In ...
www.prnewswire.com - May 16 at 5:49 PM
Amgen (AMGN) EVP Sean E. Harper Sells 1,525 SharesAmgen (AMGN) EVP Sean E. Harper Sells 1,525 Shares
www.americanbankingnews.com - May 15 at 10:10 PM
Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 16, 2018Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 16, 2018
www.nasdaq.com - May 15 at 5:40 PM
Mizuho Reiterates $200.00 Price Target for Amgen (AMGN)Mizuho Reiterates $200.00 Price Target for Amgen (AMGN)
www.americanbankingnews.com - May 15 at 1:07 PM
Better Buy: Amgen Inc. vs. Biogen Inc.Better Buy: Amgen Inc. vs. Biogen Inc.
www.fool.com - May 15 at 8:16 AM
Lillys migraine drug meets main goal in cluster headache trialLilly's migraine drug meets main goal in cluster headache trial
finance.yahoo.com - May 15 at 8:00 AM
$5.74 Billion in Sales Expected for Amgen (AMGN) This Quarter$5.74 Billion in Sales Expected for Amgen (AMGN) This Quarter
www.americanbankingnews.com - May 15 at 4:20 AM
NYSE trader: Trump will go easy on drug companies, and stocks should be just fineNYSE trader: Trump will go easy on drug companies, and stocks should be just fine
finance.yahoo.com - May 13 at 5:58 PM
Trump lets drug companies off the hookTrump lets drug companies off the hook
finance.yahoo.com - May 13 at 5:58 PM
Amgen (AMGN) Expected to Announce Earnings of $3.47 Per ShareAmgen (AMGN) Expected to Announce Earnings of $3.47 Per Share
www.americanbankingnews.com - May 13 at 8:56 AM
Head-To-Head Comparison: BioCryst Pharmaceuticals (BCRX) vs. Amgen (AMGN)Head-To-Head Comparison: BioCryst Pharmaceuticals (BCRX) vs. Amgen (AMGN)
www.americanbankingnews.com - May 11 at 7:31 PM
Amgen To Present At The Bank of America Merrill Lynch 2018 Health Care ConferenceAmgen To Present At The Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 10 at 5:38 PM
Amgen (AMGN) and CRISPR Therapeutics (CRSP) Financial ReviewAmgen (AMGN) and CRISPR Therapeutics (CRSP) Financial Review
www.americanbankingnews.com - May 9 at 3:12 AM
Amgen, Halliburton, Nvidia, Gold: Fast Money Picks For May 8Amgen, Halliburton, Nvidia, Gold: 'Fast Money' Picks For May 8
www.benzinga.com - May 8 at 8:13 AM
Final Trade: AMGN, GLD & moreFinal Trade: AMGN, GLD & more
finance.yahoo.com - May 8 at 8:13 AM
Tim's Next Big Idea: AmgenTim's Next Big Idea: Amgen
finance.yahoo.com - May 8 at 8:13 AM
How Repatha Is Positioned after 1Q18How Repatha Is Positioned after 1Q18
finance.yahoo.com - May 8 at 8:13 AM
Xgeva Could Significantly Boost Amgen’s Revenue Growth in 2018Xgeva Could Significantly Boost Amgen’s Revenue Growth in 2018
finance.yahoo.com - May 7 at 8:01 AM
Are These Disappointing Drugs Back on Track to Billions?Are These Disappointing Drugs Back on Track to Billions?
finance.yahoo.com - May 5 at 8:10 AM
3 Things In Biotech, May 2: Big CARs, Big Kar Lands, Amgen Advances3 Things In Biotech, May 2: Big CARs, Big Kar Lands, Amgen Advances
seekingalpha.com - May 3 at 8:16 AM
Ignore these giant stock buybacks and you'll miss outIgnore these giant stock buybacks and you'll miss out
finance.yahoo.com - May 3 at 8:16 AM
For Expensive New Drugs, Biopharma Should Make Money-Back Guarantees MandatoryFor Expensive New Drugs, Biopharma Should Make Money-Back Guarantees Mandatory
finance.yahoo.com - May 2 at 8:00 AM
Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To ...Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To ...
www.prnewswire.com - April 30 at 5:29 PM
Amgen (AMGN) Shares Cross 3% Yield MarkAmgen (AMGN) Shares Cross 3% Yield Mark
www.nasdaq.com - April 30 at 5:29 PM
UAB-led study shows promise for bone density drugUAB-led study shows promise for bone density drug
finance.yahoo.com - April 30 at 5:29 PM
Amgen (AMGN) Receives Positive CHMP Opinion to Add OS Results From Phase 3 ASPIRE Study to KYPROLIS LabelAmgen (AMGN) Receives Positive CHMP Opinion to Add OS Results From Phase 3 ASPIRE Study to KYPROLIS Label
www.streetinsider.com - April 30 at 9:24 AM
Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) LabelAmgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label
finance.yahoo.com - April 30 at 9:23 AM
Q3 2018 Earnings Forecast for Amgen Issued By Leerink Swann (AMGN)Q3 2018 Earnings Forecast for Amgen Issued By Leerink Swann (AMGN)
www.americanbankingnews.com - April 30 at 3:24 AM
European advisory group backs expanded use for Amgens ProliaEuropean advisory group backs expanded use for Amgen's Prolia
seekingalpha.com - April 28 at 8:00 AM
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid ...Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid ...
www.prnewswire.com - April 27 at 5:30 PM
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced OsteoporosisAmgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
finance.yahoo.com - April 27 at 5:30 PM
How Did BioMarin Pharmaceutical’s Drugs Perform in 1Q18?How Did BioMarin Pharmaceutical’s Drugs Perform in 1Q18?
finance.yahoo.com - April 27 at 5:30 PM
Gabelli Brokers Raise Earnings Estimates for Amgen (AMGN)Gabelli Brokers Raise Earnings Estimates for Amgen (AMGN)
www.americanbankingnews.com - April 27 at 11:14 AM
Q4 2018 EPS Estimates for Amgen (AMGN) Decreased by William BlairQ4 2018 EPS Estimates for Amgen (AMGN) Decreased by William Blair
www.americanbankingnews.com - April 27 at 9:39 AM
Q4 2018 EPS Estimates for Amgen (AMGN) Lowered by AnalystQ4 2018 EPS Estimates for Amgen (AMGN) Lowered by Analyst
www.americanbankingnews.com - April 27 at 9:39 AM

SEC Filings

Amgen (NASDAQ:AMGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amgen (NASDAQ:AMGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amgen (NASDAQ AMGN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.